Advertisement
Australia markets open in 8 hours 11 minutes
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • AUD/USD

    0.6503
    +0.0003 (+0.05%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.37
    -0.44 (-0.53%)
     
  • GOLD

    2,344.00
    +5.60 (+0.24%)
     
  • Bitcoin AUD

    98,106.95
    -1,330.55 (-1.34%)
     
  • CMC Crypto 200

    1,377.43
    -5.15 (-0.37%)
     

Bullish Cellebrite DI Ltd. (NASDAQ:CLBT) insiders filled their treasuries with US$15m worth of stock over last year

Multiple insiders secured a larger position in Cellebrite DI Ltd. (NASDAQ:CLBT) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Cellebrite DI

Cellebrite DI Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Director Adam Clammer for US$7.5m worth of shares, at about US$10.00 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$4.82). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

ADVERTISEMENT

In the last twelve months Cellebrite DI insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Cellebrite DI is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 6.1% of Cellebrite DI shares, worth about US$56m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Cellebrite DI Tell Us?

It doesn't really mean much that no insider has traded Cellebrite DI shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. Overall we don't see anything to make us think Cellebrite DI insiders are doubting the company, and they do own shares. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 3 warning signs for Cellebrite DI (1 is potentially serious!) that we believe deserve your full attention.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.